drugset / Trial / NCT00752037
Safety Study of Lopinavir/Ritonavir With Raltegravir in HIV-infected Patients
Non-randomizedSingle-groupOpen-labelTreatment
Summary
A single center, open label, 48-week study of lopinavir/ritonavir in combination with raltegravir. 30 patients, both naïve and experienced, will be enrolled. 15 treatment naïve patients and 15 treatment experienced patients enrolled
Timeline
- Start
- 2008-09
- Primary completion
- 2010-04
- Completion
- 2010-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Raltegravir | Other / unclassified | 400 mg | Oral |
| Subject | lopinavir/ritonavir | Unknown | 100 mg | Oral |
| Subject | lopinavir/ritonavir | Unknown | 400 mg | Oral |